Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

GSK's Blenrep Faces Setback as FDA Advisory Committee Votes Against Approval

GSK's antibody-drug conjugate Blenrep has encountered a significant obstacle in its bid to return to the market for multiple myeloma treatment. The U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee (ODAC) voted against recommending approval for two proposed combination regimens, citing safety concerns and inadequate dosing optimization.

NoahAI News7/19/2025

Flagship's Sail Biomedicines Restructures, Focuses on Immunology Pipeline

Sail Biomedicines, a Flagship Pioneering-backed biotech company, has announced a significant restructuring effort, marking its second round of layoffs this year. The move comes as the company sharpens its focus on immunology and its promising in vivo CAR-T cell therapy program.

NoahAI News7/19/2025

Sarepta Faces Setback as Third Patient Death Reported, Prompting Restructuring and Safety Concerns

Sarepta Therapeutics, a prominent player in the gene therapy space, has encountered a significant setback with the revelation of a third patient death linked to one of its investigational treatments. This development comes on the heels of a major corporate restructuring and has sparked renewed concerns about the safety of the company's gene therapy pipeline.

NoahAI News7/19/2025

Heartflow's $100M IPO Filing Signals Renewed Push for AI-Powered Coronary Diagnostics

Heartflow, a developer of artificial intelligence-powered diagnostics for coronary artery disease, has filed for a $100 million initial public offering (IPO) on the Nasdaq, marking a significant milestone in the company's journey to revolutionize cardiac care. This move comes after the company's previous attempt to go public through a special purpose acquisition company (SPAC) deal was abandoned in 2022 due to unfavorable market conditions.

NoahAI News7/19/2025

Pharmaceutical Industry Roundup: Mixed Results for Bristol Myers and GSK, Leadership Changes at PureTech

Bristol Myers Squibb announced that its anemia treatment, Reblozyl, failed to meet its primary goal in a Phase 3 study for patients with myelofibrosis-related anemia. Despite this setback, the company reported a "numerical and clinically meaningful" improvement in patients achieving independence from red blood cell transfusions compared to placebo. Bristol Myers remains optimistic about the drug's potential and plans to discuss possible approval applications with regulators.

NoahAI News7/19/2025

Carlsmed Aims for $103M IPO to Fuel Growth in Custom Spine Surgery Market

Carlsmed, a rapidly growing player in the custom spine surgery market, has set its sights on raising up to $103.3 million through an initial public offering (IPO) to support the development and commercialization of its innovative spine surgery platform. The company plans to offer 6.7 million shares of common stock at an expected range of $14 to $16 per share, with an additional option for underwriters to purchase over 1 million shares.

NoahAI News7/19/2025

RFK Jr. Reshapes HHS Leadership and Policies in Controversial Moves

In a series of dramatic changes at the Department of Health and Human Services (HHS), Secretary Robert F. Kennedy Jr. has implemented sweeping personnel and policy shifts that are sending shockwaves through the healthcare industry. These developments mark a significant departure from previous administrations' approaches and have raised concerns among health experts.

NoahAI News7/19/2025

FDA Rejects Roche's Columvi for Earlier DLBCL Treatment, Citing Insufficient U.S. Data

The U.S. Food and Drug Administration (FDA) has declined to approve Roche's Columvi for the treatment of second-line diffuse large B-cell lymphoma (DLBCL) patients who are not eligible for autologous stem cell transplant. The decision, announced by Roche and its subsidiary Genentech on July 18, 2025, comes as a setback for the pharmaceutical giant's efforts to expand the use of Columvi in earlier treatment settings.

NoahAI News7/19/2025

Sarepta Faces Setback as Third Patient Dies in Gene Therapy Trials

Sarepta Therapeutics, a leading biotechnology company, has reported a third patient death related to its gene therapy programs, raising concerns about the safety of its treatments and potentially impacting the company's future direction.A 51-year-old man participating in a Phase I study for limb-girdle muscular dystrophy (LGMD) died in June after receiving Sarepta's investigational gene therapy SRP-9004. The cause of death was acute liver failure, the same complication responsible for two previous fatalities linked to Sarepta's Duchenne muscular dystrophy (DMD) treatment, Elevidys.

NoahAI News7/18/2025

Bain Capital and Botanic Properties Break Ground on Innovative Biomanufacturing Facility in Massachusetts

In a significant development for the biopharmaceutical industry, Bain Capital and Botanic Properties have commenced construction on a cutting-edge biomanufacturing facility in Bedford, Massachusetts. The joint venture, known as GenesisM, aims to address the growing demand for flexible and efficient manufacturing spaces in the life sciences sector.

NoahAI News7/18/2025

Biotech Venture Funding Plummets in Q2 2025, HSBC Report Reveals

Venture capital funding for biotechnology startups has experienced a significant downturn in the second quarter of 2025, according to a new report from HSBC Innovation Banking. The decline has erased the promising start to the year, raising concerns about the future of biotech innovation and investment.

NoahAI News7/18/2025

Agilent Technologies CFO Bob McMahon Announces Resignation, Company Reaffirms Q3 Guidance

Agilent Technologies, a leading provider of laboratory instruments, has announced the resignation of its Chief Financial Officer, Bob McMahon. The unexpected departure comes as the company maintains its financial outlook for the third quarter of 2025.

NoahAI News7/18/2025

«1...10 11 12...67 »